Overview

Anti-MAG First Administration to Human

Status:
Completed
Trial end date:
2009-04-09
Target enrollment:
Participant gender:
Summary
GSK249320 is a monoclonal antibody directed against myelin associated glycoprotein (MAG), a protein that inhibits axonal regeneration. GSK249320 acts as a MAG antagonist, and through this activity it is hypothesised that it will enhance recovery from neuronal degeneration following acute axonal injury, which occurs in spinal cord injury or stroke.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline